Are fragmented and reduced slow-wave sleep linked to amyloid and tau burden?

Sleep continuity and slow-wave sleep are increasingly relevant to Alzheimer-related biomarker biology, particularly in older adults, but the evidence supports association and biologic plausibility more strongly than proven causation.

Clinical and biomarker evidence

• In adults aged ≥65 years, greater night-to-night actigraphic sleep-fragmentation variability has been associated with higher amyloid-PET burden, including in frontal, parietal, and precuneus regions. In a cognitively unimpaired familial-risk cohort, greater fragmentation variability was associated with both amyloid and tau burden.
• Among older adults with insomnia, more polysomnographic wake after sleep onset correlated with greater amyloid burden. Findings are not uniform: another PET study found only a marginal fragmentation–tau association and no amyloid association.
• Lower NREM slow-wave activity, especially 1–2 Hz activity, is associated with greater tau-related pathology in older adults. Frontal slow-wave activity has also been associated with CSF Aβ42 after adjustment in cognitively normal older adults.

Mechanistic evidence

• In mice, 30 days of chronic sleep fragmentation reduced CSF tracer influx into brain, tracer efflux to deep cervical lymph nodes, and clearance of injected amyloid-β. It also suppressed slow arterial vasomotion, a plausible driver of impaired brain-fluid transport. No significant tracer differences after 3 days suggest chronicity may matter.
• In humans, sham-controlled disruption of slow-wave activity increased the next-morning rise in CSF Aβ40 independent of sleep duration or efficiency. This supports altered amyloid dynamics, although CSF concentration changes cannot distinguish reduced clearance from altered production, release, or distribution.

Interpretation and clinical implications

• Most human biomarker studies are cross-sectional and observational. Sleep apnea, vascular disease, depression, medications, and preclinical Alzheimer pathology itself may contribute to both disturbed sleep and biomarker burden.
• For an 84-year-old, persistent fragmentation warrants evaluation for modifiable contributors, particularly sleep-disordered breathing and medication effects; it should not be viewed as proof of ongoing amyloid or tau accumulation.

Bottom line

• Fragmented sleep and reduced slow-wave sleep are moderately supported correlates of greater amyloid and tau burden; impaired metabolite clearance is directly demonstrated chiefly in chronic-fragmentation animal studies and remains plausible, rather than proven, in humans.